/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Zura Bio Ltd Share Price Today: Live Updates & Key Insights

Zura Bio Ltd share price today is $6.92, up -2.86%. The stock opened at $7 against the previous close of $6.99, with an intraday high of $7 and low of $6.61.

Zura Bio Ltd Share Price Chart

style
pb-0

Zura Bio Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Zura Bio Ltd Share Price Performance

$6.92 -0.0286(-2.86%) ZURA at 13 Mar 2026 04:01 PM Biotechnology
Lowest Today 6.61
Highest Today 7
Today’s Open 7
Prev. Close 6.99
52 Week High 7.44
52 Week Low 0.97
Day’s Range: Low 6.61 High 7
52-Week Range: Low 0.97 High 7.44
1 day return -
1 Week return -2.79
1 month return +11.25
3 month return +64.72
6 month return +250.77
1 year return +532.71
3 year return -28.81
5 year return -30.34
10 year return -

Zura Bio Ltd Institutional Holdings

Zura Bio Ltd Market Status

Strong Buy: 5

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Zura Bio Ltd Fundamentals

Market Cap 663.22 M

PB Ratio 6.0745

PE Ratio 0.0

Enterprise Value 518.51 M

Total Assets 179.53 M

Volume 440635

Zura Bio Ltd Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M

Annual Net worth FY23:-60360000 -60.4M, FY22:-25738000 -25.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-14000 -0.0M, Q2/2025:-11000 -0.0M, Q1/2025:-9000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-1000 -0.0M

Quarterly Net worth Q3/2025:-20037000 -20.0M, Q2/2025:-15993000 -16.0M, Q1/2025:-17442000 -17.4M, Q3/2024:-20702000 -20.7M, Q2/2024:-12666000 -12.7M

About Zura Bio Ltd & investment objective

Company Information Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Organisation Biotechnology

Employees 30

Industry Biotechnology

CEO Dr. Sandeep C. Kulkarni M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow